1. Home
  2. LBRDA vs RYTM Comparison

LBRDA vs RYTM Comparison

Compare LBRDA & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Liberty Broadband Corporation

LBRDA

Liberty Broadband Corporation

HOLD

Current Price

$34.99

Market Cap

7.2B

ML Signal

HOLD

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$108.96

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LBRDA
RYTM
Founded
2014
2008
Country
United States
United States
Employees
1900
N/A
Industry
Cable & Other Pay Television Services
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.2B
5.8B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
LBRDA
RYTM
Price
$34.99
$108.96
Analyst Decision
Strong Buy
Analyst Count
0
14
Target Price
N/A
$131.14
AVG Volume (30 Days)
189.0K
862.0K
Earning Date
05-07-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
28.34
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$55.34
Revenue Next Year
$109.28
$86.06
P/E Ratio
$8.39
N/A
Revenue Growth
N/A
N/A
52 Week Low
$29.18
$62.84
52 Week High
$100.71
$122.20

Technical Indicators

Market Signals
Indicator
LBRDA
RYTM
Relative Strength Index (RSI) 56.76 75.51
Support Level $31.91 $98.30
Resistance Level $34.90 $113.03
Average True Range (ATR) 1.59 5.27
MACD 0.54 2.16
Stochastic Oscillator 55.73 90.73

Price Performance

Historical Comparison
LBRDA
RYTM

About LBRDA Liberty Broadband Corporation

Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services, including video, internet, voice, and mobile services; commercial services, including small and medium business and enterprise solutions; advertising services; and other services. The company's reportable segments are GCI Holdings and Charter. The firm derives the majority of its revenue from GCI Holdings.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Share on Social Networks: